创新药子公司将作为公司布局创新药领域的核心载体，围绕存在重大未被满足临床需求的疾病领域进行 前瞻性布局，将重点关注免疫抗肿瘤、自身免疫性疾病等方向，并视研发进展及市场环境变化，适时拓 展至心血管、内分泌等其他具有发展潜力的领域。创新药子公司将借鉴行业成熟运营模式，通过自主研 发、产品引进及收购、合资共建、股权投资等多维方式推进创新药管线建设，构建研发、转化、产业化 全链条闭环运营体系，提升公司在创新药领域的专业化投资与市场化运营能力。 格隆汇1月26日丨成大生物(688739.SH)公布，为落实公司疫苗与创新药双轮驱动的长期发展战略，把握 创新生物药领域的发展机遇，公司拟以自有资金10亿元设立创新药子公司，持有其100%股权。为提高 资金使用效率，注册资本将根据业务拓展节奏及研发项目进度分期注入，实现资金投入与项目需求的动 态匹配。该创新药子公司将专注于创新药研发、优质项目引进与并购、核心团队搭建及专业化运营体系 建设，助力公司打造第二增长曲线。 ...

Core Viewpoint - The approval of Lonapegsomatropin (SKYTROFA) by the National Medical Products Administration of China marks a significant advancement in the treatment of pediatric growth hormone deficiency, providing a long-acting alternative to daily injections [1][2]. Group 1: Product Approval and Efficacy - Lonapegsomatropin has received a Biologics License Application (BLA) approval for treating growth hormone deficiency in children aged 3 years and older in China [1]. - The drug has demonstrated superior efficacy in a Phase 3 trial, showing an annualized height velocity of 10.66 cm/year compared to 9.75 cm/year for daily injections, with a statistically significant difference of 0.91 cm/year (P=0.0010) [2]. - The height standard deviation score (SDS) increased by 1.01 in the Lonapegsomatropin group versus 0.83 in the daily injection group, with a p-value of 0.0015, indicating significant improvement from week 13 of treatment [2]. Group 2: Commercialization Strategy - Following the BLA approval, the company has initiated a comprehensive commercialization plan to ensure supply and expand market coverage [3]. - A commercial supply agreement has been established with Ascendis Pharma to secure the availability of Lonapegsomatropin upon market launch [3]. - The company is enhancing its commercialization capabilities through a dedicated team and tailored strategies for market access and physician awareness, alongside strategic partnerships with Shanghai Pharmaceuticals, United Family Healthcare, and Anke Bioengineering for distribution and promotion [3].

Core Viewpoint - Wantai Biological's subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received confirmation from the World Health Organization (WHO) regarding the prequalification of its bivalent human papillomavirus (HPV) vaccine, following its initial WHO PQ certification in 2021 [1] Group 1 - The bivalent HPV vaccine is a preventive biological product developed by Wantai Canghai, which received drug registration approval from the National Medical Products Administration on December 30, 2019 [1] - The vaccine was officially launched in mainland China (excluding Hong Kong, Macau, and Taiwan) in May 2020, targeting women aged 9 to 45 [1] - The vaccine is designed to prevent cervical cancer and related conditions caused by high-risk HPV types 16 and 18, including CIN2/3, adenocarcinoma in situ (AIS), and CIN1, as well as persistent infections caused by these HPV types [1]

Core Viewpoint - The company has officially launched Phase I clinical trials for its recombinant hexavalent norovirus vaccine (Pichia pastoris) in mainland China, marking a significant step in its vaccine development efforts [1] Group 1: Vaccine Development - The recombinant hexavalent norovirus vaccine is developed using genetic engineering technology based on virus-like particles (VLPs) [1] - This innovative vaccine is designed to prevent norovirus infections and the acute gastroenteritis they cause [1] - The vaccine theoretically has the potential to prevent over 90% of norovirus infections and related acute gastroenteritis [1]

格隆汇1月26日丨辽宁成大(600739.SH)公布，成大生物为推进发展战略，积极把握创新生物药领域的发 展机遇，拟以自有资金10亿元投资设立全资子公司成大生物创新制药有限公司（暂定名）。成大生物持 有该子公司100%股权，出资资金将专项用于创新药研发、优质项目引进与并购、核心团队搭建及专业 化运营体系建设，为其打造第二增长曲线。 创新药子公司将作为成大生物布局创新药领域的核心载体，围绕存在重大未被满足临床需求的疾病领域 进行前瞻性布局，将重点关注免疫抗肿瘤、自身免疫性疾病等方向，并视研发进展及市场环境变化，适 时拓展至心血管、内分泌等其他具有发展潜力的领域。创新药子公司将借鉴行业成熟运营模式，通过自 主研发、产品引进及收购、合资共建、股权投资等多维方式推进创新药管线建设，构建研发、转化、产 业化全链条闭环运营体系，提升公司在创新药领域的专业化投资与市场化运营能力。 ...

每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，三生国健1月26日晚间发布业绩预告，公司2025年度预计实现归属于母公司所有者的净利 润29亿元左右，与上年同期相比，将增加21.95亿元左右，相比上年同期涨幅约311.35%。业绩变动主要 原因是，报告期内，公司与辉瑞公司达成重要合作；公司收到辉瑞公司就707项目支付的授权许可首付 款并相应确认收入约28.9亿元人民币，导致2025年度的营业收入、归属于母公司所有者的净利润以及扣 除非经常损益后归属于母公司所有者的净利润均出现较大幅度的增长。 每日经济新闻 （记者 王晓波） ...

Group 1 - The company Microchip Biotech expects to achieve a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168 million yuan compared to the same period last year, thus turning a profit [1] - The significant change in performance is attributed to the product Sigleptin's unique clinical value in "diabetes and liver management," along with efforts in self-operated, strategic partnerships, and new retail channels, resulting in a sales revenue increase of approximately 123% year-on-year [1] - The product Sidabenamine has gained support from the National Healthcare Security Administration and market recognition, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Catalog in January 2025, leading to a year-on-year sales revenue growth of about 16% [1]

据计算，Q4净利润预计25.01亿元，环比增长1097%。第四季度净利润分析师一致预测是18.63亿，业绩 高于预期。 格隆汇1月26日｜三生国健(688336.SH)发布2025年年度业绩预告，预计归属于上市公司股东的净利润为 29.00亿元左右，比上年同期增长311.35%。报告期内，公司与辉瑞公司（PfizerInc.）达成重要合作；公 司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.90亿元人民币，导致2025年度的 营业收入、归属于母公司所有者的净利润以及扣除非经常损益后归属于母公司所有者的净利润均出现较 大幅度的增长。 ...

Core Viewpoint - Sanofi Guojian (688336.SH) forecasts a significant increase in net profit for 2025, projecting approximately 2.9 billion yuan, representing a year-on-year growth of 311.35% [1] Financial Performance - The company expects substantial growth in operating revenue and net profit attributable to shareholders due to a key collaboration with Pfizer Inc. [1] - The revenue recognized from Pfizer for the 707 project is approximately 2.89 billion yuan, contributing to the anticipated increase in financial metrics for 2025 [1]

Core Viewpoint - Microchip Biotech (688321.SH) expects to achieve an annual revenue of approximately 910.08 million yuan in 2025, representing a year-on-year growth of about 38.32% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 53.46 million yuan in 2025, an increase of about 168.03 million yuan compared to the previous year, marking a turnaround from losses to profits [1] - The expected net profit excluding non-recurring gains and losses is around 38.14 million yuan [1] Product Performance - The product Sigleptin Sodium has shown significant commercial success with a sales revenue increase of approximately 123% year-on-year, driven by its unique clinical value in "diabetes and liver management" and enhanced distribution through self-operated, strategic partners, and new retail channels [1] - The product Sidabenamine has gained recognition for its clinical value, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025, leading to a year-on-year sales revenue growth of about 16% [1]